NCT00572754

Brief Summary

The objective of this clinical investigation is to provide the first and preliminary clinical data to study the safety and efficacy of male circumcision where the dry circumcision method is employed.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
15

participants targeted

Target at below P25 for phase_2

Timeline
Completed

Started Nov 2007

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2007

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

December 12, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 13, 2007

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2008

Completed
Last Updated

December 13, 2007

Status Verified

December 1, 2007

First QC Date

December 12, 2007

Last Update Submit

December 12, 2007

Conditions

Outcome Measures

Primary Outcomes (1)

  • The operative and short-term post-operative safety rates

    1 month

Secondary Outcomes (1)

  • Mobibidity and mortality The length of the residual foreskin.

    1 month

Interventions

CircumcisionPROCEDURE

Circumcision by tying a ligature around the foreskin.

Eligibility Criteria

Age21 Years+
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male subjects, aged 21 years or above at the point of screening for participation.
  • Subjects who are able to give voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained.
  • Subjects who, in the opinion of the clinical investigator, are able to understand this clinical investigation co-operate with the investigational procedures and are willing to return to the clinical centre for all the required post-treatment follow-ups.
  • Subjects willing to be circumcised for cultural reasons.
  • Subjects living in the site's area.
  • Subjects who can be easily contacted by telephone.
  • Subjects who can correctly speak and correctly read English.

You may not qualify if:

  • Subjects who, in the opinion of the investigator, have an existing condition that would compromise their participation and follow-up in this study.
  • Subjects who are circumcised (i.e. subjects with a foreskin unable to cover the entire glans without pulling on the foreskin).
  • Subjects with a disease which is an indication for circumcision: phimosis, paraphimosis, warts under the prepuce, torn or tight frenulum.
  • Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes.
  • Subjects who have participated in a clinical study with an investigational product in the last 6 months.
  • Subjects who have an abnormal penile anatomy.
  • Subjects who are currently involved in any injury litigation claims.
  • Subjects who have penile diseases or lesions.
  • Subjects who have clinical symptoms of sexually transmitted infections.
  • Subjects with opportunistic infections.
  • Subjects with known diabetes, known allergy to local anaesthesia or with known abnormal blood coagulation.
  • Subjects whose penile circumference is higher (\>3mm) or lower (\<3mm) than the available circumcision tubes.
  • Subjects with a thick foreskin (difference between the diameter of covered glans and uncovered glans \> 5mm).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Teaching Hospital

Lusaka, Zambia

RECRUITING

MeSH Terms

Interventions

Circumcision, Male

Intervention Hierarchy (Ancestors)

Body Modification, Non-TherapeuticCosmetic TechniquesTherapeuticsSurgical Procedures, OperativeUrologic Surgical Procedures, MaleUrologic Surgical ProceduresUrogenital Surgical Procedures

Study Officials

  • Bertran Auvert, MD, PhD

    UVSQ-INSERM-France

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Kasonde Bowa, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NA
Masking
NONE
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

December 12, 2007

First Posted

December 13, 2007

Study Start

November 1, 2007

Study Completion

March 1, 2008

Last Updated

December 13, 2007

Record last verified: 2007-12

Locations